[go: up one dir, main page]

MX2012007325A - Capsula de abt-263. - Google Patents

Capsula de abt-263.

Info

Publication number
MX2012007325A
MX2012007325A MX2012007325A MX2012007325A MX2012007325A MX 2012007325 A MX2012007325 A MX 2012007325A MX 2012007325 A MX2012007325 A MX 2012007325A MX 2012007325 A MX2012007325 A MX 2012007325A MX 2012007325 A MX2012007325 A MX 2012007325A
Authority
MX
Mexico
Prior art keywords
phospholipid
capsule
abt
pharmaceutically acceptable
glycerides
Prior art date
Application number
MX2012007325A
Other languages
English (en)
Inventor
Ping Tong
Katherine Heemstra
Nathaniel Catron
Deliang Zhou
Eric A Schmitt
Cristina M Fischer
Geoff G Z Zhang
Yeshwant D Sanzgiri
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2012007325A publication Critical patent/MX2012007325A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Una cápsula farmacéutica comprende una caparazón que tiene encapsulado dentro del mismo una solución de líquido de ABT-263 o una sal farmacéuticamente aceptable del mismo en un vehículo substancialmente no etanólico que comprende como excipientes farmacéuticamente aceptables (a) por lo menos un fosfolípido, (b) al menos un agente de solubilización para dicho al menos un fosfolípido, seleccionado del grupo consistente de glicoles, glicéridos, y mezclas de los mismos, (c) al menos un tensioactivo que no es fosfolípido y (d) al menos un antioxidante que contiene azufre. La cápsula es útil en el tratamiento de una enfermedad caracterizada por la sobreexpresión de una o más proteínas antiapoptóticas de la familia Bcl-2, por ejemplo cáncer.
MX2012007325A 2009-12-22 2010-12-21 Capsula de abt-263. MX2012007325A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28928909P 2009-12-22 2009-12-22
PCT/US2010/061588 WO2011079127A1 (en) 2009-12-22 2010-12-21 Abt-263 capsule

Publications (1)

Publication Number Publication Date
MX2012007325A true MX2012007325A (es) 2012-07-20

Family

ID=44187848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007325A MX2012007325A (es) 2009-12-22 2010-12-21 Capsula de abt-263.

Country Status (16)

Country Link
US (1) US8927009B2 (es)
EP (1) EP2515883A4 (es)
JP (1) JP5779591B2 (es)
KR (1) KR20120098915A (es)
CN (1) CN102655858B (es)
AU (1) AU2010336518B2 (es)
BR (1) BR112012014499A2 (es)
CA (1) CA2780177A1 (es)
IL (1) IL219921A0 (es)
MX (1) MX2012007325A (es)
NZ (1) NZ599941A (es)
RU (1) RU2550956C2 (es)
SG (2) SG10201500152UA (es)
TW (1) TWI508729B (es)
WO (1) WO2011079127A1 (es)
ZA (1) ZA201203627B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
ES2687705T3 (es) 2012-07-19 2018-10-26 Fujifilm Corporation Composición líquida que contiene un principio activo a base de taxano, proceso de producción de la misma y preparación medicinal líquida
CN102836160A (zh) * 2012-10-10 2012-12-26 武汉大学 一种治疗癌症的组合药物
SG11201600107RA (en) * 2013-07-08 2016-02-26 Abbvie Inc Stabilized pharmaceutical dosage forms comprising atrasentan
KR102287342B1 (ko) * 2014-01-21 2021-08-06 비피에스아이 홀딩스, 엘엘씨. 중쇄 글리세라이드를 함유하는 속방형 필름 코팅물 및 이를 코팅한 기질
US11027021B2 (en) * 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
MX2022005375A (es) 2019-11-05 2022-10-07 Abbvie Inc Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax.

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
WO1995014037A1 (en) * 1993-11-17 1995-05-26 Ibah, Inc. Transparent liquid for encapsulated drug delivery
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
CZ20031902A3 (cs) 2001-01-31 2004-07-14 Pfizer Products Inc. Etherové deriváty užitečné jako inhibitory isozymů PDE4
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
EP1480679B1 (en) 2002-02-26 2007-05-23 Astrazeneca AB Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
CA2507522C (en) * 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
NZ561609A (en) * 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
CN1706371B (zh) 2005-05-27 2010-11-10 沈阳药科大学 一种高效的马蔺子素制剂及其制备方法
SI1933809T1 (sl) 2005-10-11 2012-08-31 Yissum Res Dev Co Sestavki za mazalno dajanje
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US20080085313A1 (en) * 2006-05-15 2008-04-10 Given Bruce D Methods and compositions for treatment of sleep apnea
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US7842681B2 (en) 2006-09-05 2010-11-30 Abbott Laboratories Treatment of myeoproliferative diseases
AU2007305423A1 (en) * 2006-09-28 2008-04-10 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
EP3424525A1 (en) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Vaccine nanotechnology
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
CA2708223A1 (en) 2007-12-06 2009-06-11 Andrew Krivoshik Oral compositions of abt-263 for treating cancer
CN101220008B (zh) 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
DE102008040935A1 (de) * 2008-08-01 2010-02-04 BSH Bosch und Siemens Hausgeräte GmbH Küchengerät mit Motordrehzahlanzeige
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
MX2011013797A (es) 2009-06-18 2012-01-30 Abbott Lab Suspension de farmaco estable de nanoparticula.
CN105820138A (zh) 2009-09-20 2016-08-03 Abbvie 公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备

Also Published As

Publication number Publication date
IL219921A0 (en) 2012-07-31
US20110159085A1 (en) 2011-06-30
WO2011079127A1 (en) 2011-06-30
AU2010336518B2 (en) 2014-03-06
EP2515883A1 (en) 2012-10-31
SG10201500152UA (en) 2015-03-30
JP5779591B2 (ja) 2015-09-16
AU2010336518A1 (en) 2012-06-07
SG181916A1 (en) 2012-08-30
NZ599941A (en) 2014-06-27
CN102655858B (zh) 2015-11-25
EP2515883A4 (en) 2013-07-17
ZA201203627B (en) 2013-01-30
CA2780177A1 (en) 2011-06-30
RU2012131408A (ru) 2014-01-27
TWI508729B (zh) 2015-11-21
RU2550956C2 (ru) 2015-05-20
TW201130493A (en) 2011-09-16
JP2013515078A (ja) 2013-05-02
US8927009B2 (en) 2015-01-06
BR112012014499A2 (pt) 2016-08-16
CN102655858A (zh) 2012-09-05
KR20120098915A (ko) 2012-09-05

Similar Documents

Publication Publication Date Title
MX2012007325A (es) Capsula de abt-263.
MY160603A (en) Stabilized lipid formulation of apoptosis promoter
MX2011011511A (es) Sal de abt-263 y fomas en estado solido de la misma.
MX2012003408A (es) Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.
MX349533B (es) Dispersiones solidas que contienen un agente inductor de apoptosis.
UY32599A (es) Formulación oral sólida de abt-263
NZ606194A (en) Isoxazoline derivatives as antiparasitic agents
MX2010003868A (es) Cis-imidazolinas quirales.
PH12015500297A1 (en) Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
MX2011012122A (es) Derivados de tiofeno.
MX2012004148A (es) Compuestos de dioxido de iminotiadiazina como inhibidores de la enzima de disociacion de la proteina precursora amiloide en el sitio beta, composiciones, y su uso.
EA200901319A1 (ru) Композиции для назального введения
NZ597248A (en) Solid dispersions containing an apoptosis-promoting agent
MX393195B (es) Capsula de estradiol soluble para insercion por via vaginal
EA017091B9 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
WO2012168885A9 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
MX355683B (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
PL1940249T3 (pl) Nowe formulacje rozpuszczalnych w tłuszczach składników aktywnych o wysokiej biodostępności
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
MX2012008039A (es) Formulacion farmaceutica para proteinas.
EP2560642A4 (en) TREATMENT OF GICHT
MX2014002362A (es) Formulaciones y formas de dosificacion de fosfolipidos oxidados.
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
PH12013500173A1 (en) Oral controlled release pharmaceutical compositions of blonanserin

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration